Dimensional Fund Advisors
RXRX icon

Dimensional Fund Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Dimensional Fund Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.6K Sell
21,678
-8,382
-28% -$32.4K ﹤0.01% 3154
2025
Q4 		$123K Buy
+30,060
New +$149K ﹤0.01% 3131
2025
Q3 		– Sell
-34,053
Closed -$172K – 3334
2025
Q2 		$172K Sell
34,053
-1,682,722
-98% -$8.27M ﹤0.01% 3134
2025
Q1 		$9.09M Buy
1,716,775
+8,735
+0.5% +$63.7K ﹤0.01% 2290
2024
Q4 		$11.5M Sell
1,708,040
-9,739
-0.6% -$65.5K ﹤0.01% 2250
2024
Q3 		$11.3M Sell
1,717,779
-202,398
-11% -$1.45M ﹤0.01% 2249
2024
Q2 		$14.4M Sell
1,920,177
-174,823
-8% -$1.52M ﹤0.01% 2109
2024
Q1 		$20.9M Sell
2,095,000
-42,110
-2% -$469K 0.01% 1959
2023
Q4 		$21.1M Buy
2,137,110
+1,291,946
+153% +$9.21M 0.01% 1959
2023
Q3 		$6.47M Buy
845,164
+60,376
+8% +$602K ﹤0.01% 2443
2023
Q2 		$5.86M Buy
784,788
+87,503
+13% +$612K ﹤0.01% 2468
2023
Q1 		$4.65M Buy
697,285
+507,357
+267% +$4.02M ﹤0.01% 2504
2022
Q4 		$1.46K Buy
+189,928
New +$1.86M ﹤0.01% 2810

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors's RXRX Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 28% in Q1 2026, selling an estimated $32.4K and leaving 21,678 shares worth $66.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Dimensional Fund Advisors first reported a position in RXRX in Q4 2022 and has held it in 13 quarters since. The position peaked at $21.1M in Q4 2023. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Dimensional Fund Advisors held 21,678 shares of Recursion Pharmaceuticals worth $66.6K as of Q1 2026.
  • Dimensional Fund Advisors sold 8,382 Recursion Pharmaceuticals shares in Q1 2026, an estimated $32.4K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #3154 holding.
  • Dimensional Fund Advisors first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • Dimensional Fund Advisors's Recursion Pharmaceuticals position peaked at $21.1M in Q4 2023.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.